Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from $17 billion approach from Johnson & Johnson.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
Johnson & Johnson has some of the world's best-known health and personal care brands, while Actelion manufactures popular treatments for pulmonary arterial hypertension.
